Prostate Cancer Research Institute

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Celestia S. Higano, Andrew J. Armstrong, Oliver Sartor et al. · Cancer · 2019 · 71 citations · Full text

Medicine, Oncology, Urology +17

Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl

Tony Truong, Guizhen Sun, Michael Doorly et al. · Proceedings of the National Academy of Sciences · 2003 · 68 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off Therapy

Stephen B. Strum, Mark C. Scholz, Jonathan E. McDermed · The Oncologist · 2000 · 67 citations · Full text

Medicine, Endocrinology, Oncology +17

Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

Charles J. Rosser, Yosuke Hirasawa, Jared D. Acoba et al. · Journal of Clinical Oncology · 2020 · 13 citations

Medicine, Oncology, Pharmacology +17

Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer

Mark C. Scholz, Richard Y. Lam, Stephen B. Strum et al. · Clinical Genitourinary Cancer · 2011 · 12 citations

Medicine, Oncology, Urology +12